Literature DB >> 25748320

Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.

Anja W Olsen1, Frank Follmann1, Karin Erneholm2, Ida Rosenkrands1, Peter Andersen1.   

Abstract

The VD4 region from the Chlamydia trachomatis major outer membrane protein contains important neutralizing B-cell epitopes of relevance for antibody-mediated protection against genital tract infection. We developed a multivalent vaccine construct based on VD4s and their surrounding constant segments from serovars D, E, and F. Adjuvanted with cationic liposomes, this construct promoted strong immune responses to serovar-specific epitopes, the conserved LNPTIAG epitope and neutralized serovars D, E, and F. Vaccinated mice were protected against challenge, with protection defined as reduced bacterial numbers in vagina and prevention of pathological changes in the upper genital tract. Adoptive transfer of serum and T-cell depletion experiments demonstrated a dominant role for antibodies and CD4(+) T cells in the protective immune response. Integrating a multivalent VD4 construct into the sequence of the major outer membrane protein resulted in a protective and broadly neutralizing vaccine. Our findings emphasize the important role of antibodies in protection against Chlamydia trachomatis.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chlamydia trachomatis; VD4; broadly neutralizing Ab; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25748320     DOI: 10.1093/infdis/jiv137

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

1.  Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge.

Authors:  Nina Dieu Nhien Tran Nguyen; Anja W Olsen; Emma Lorenzen; Peter Andersen; Malene Hvid; Frank Follmann; Jes Dietrich
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

2.  A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.

Authors:  Sukumar Pal; Olga V Tatarenkova; Luis M de la Maza
Journal:  Immunology       Date:  2015-10-01       Impact factor: 7.397

Review 3.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

4.  Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection.

Authors:  Toni Darville; Hannah L Albritton; Wujuan Zhong; Li Dong; Catherine M O'Connell; Taylor B Poston; Alison J Quayle; Nilu Goonetilleke; Harold C Wiesenfeld; Sharon L Hillier; Xiaojing Zheng
Journal:  Am J Reprod Immunol       Date:  2019-03-18       Impact factor: 3.886

5.  Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.

Authors:  Signe Tandrup Schmidt; Malene Aaby Neustrup; Stine Harloff-Helleberg; Karen Smith Korsholm; Thomas Rades; Peter Andersen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2017-05-17       Impact factor: 4.200

Review 6.  Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Expert Rev Vaccines       Date:  2016-03-21       Impact factor: 5.217

7.  Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia.

Authors:  C P O'Meara; C W Armitage; A Kollipara; D W Andrew; L Trim; M B Plenderleith; K W Beagley
Journal:  Mucosal Immunol       Date:  2015-12-09       Impact factor: 7.313

8.  B Cell Presentation of Chlamydia Antigen Selects Out Protective CD4γ13 T Cells: Implications for Genital Tract Tissue-Resident Memory Lymphocyte Clusters.

Authors:  Raymond M Johnson; Hong Yu; Norma Olivares Strank; Karuna Karunakaran; Ying Zhu; Robert C Brunham
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

9.  A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility.

Authors:  Delia F Tifrea; Sukumar Pal; Luis M de la Maza
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

10.  Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.

Authors:  Kathryn M Frietze; Rebeccah Lijek; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2018-10-20       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.